BC Week In Review | Aug 5, 2013
Company News

Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news

Cornerstone filed a suit in the U.S. District Court for the District of Delaware alleging that an sNDA submitted by Exela for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine in 0.9% sodium chloride...
BC Week In Review | Jun 17, 2013
Company News

Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news

Cornerstone received a Paragraph IV notification letter from Exela PharmaSci's Exela Pharma Sciences LLC (Lenoir, N.C.) subsidiary indicating that it submitted an sNDA to FDA for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine...
BioCentury | Apr 22, 2013
Emerging Company Profile

Cardiorentis: Keeping heart

Cardiorentis AG is the fifth company to take on development of ularitide for acute heart failure. Armed with more than €100 million ($129.9 million) from undisclosed investors and expecting to have to do a smaller...
BC Week In Review | Sep 24, 2012
Company News

Dara BioSciences, Helsinn Group sales and marketing update

Helsinn granted Dara exclusive, U.S. rights to commercialize Gelclair povidone. The bioadherent oral gel is approved in the U.S. to treat oral mucositis. Dara plans to launch Gelclair in 1Q13. Dara and Helsinn declined to...
BC Week In Review | Sep 10, 2012
Company News

Civitas management update

Civitas Therapeutics Inc. , Chelsea, Mass.   Business: Drug delivery, Neurology, Pulmonary   Hired: Bryan Stuart as CBO, formerly chief of corporate development of EKR Therapeutics Inc. , which Cornerstone Therapeutics Inc. acquired  ...
BC Week In Review | Jul 2, 2012
Company News

Cornerstone Therapeutics, EKR deal

Cornerstone acquired EKR for $125 million in cash plus up to $25 million in milestones over the next three years (see BioCentury, May 21). Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C.   EKR Therapeutics Inc. , Bedminster,...
BC Week In Review | May 21, 2012
Company News

Cornerstone Therapeutics, EKR deal

Cornerstone will acquire EKR for $125 million in cash plus up to $25 million in milestones over the next three years. Cornerstone said the deal expands its product offerings and commercial infrastructure in the hospital...
BC Week In Review | Feb 13, 2012
Company News

Nestle management update

Nestle S.A. (SIX:NESN), Vevey, Switzerland   Business: Gastrointestinal, Autoimmune, Diagnostic   Hired: Anthony Yost as SVP and chief commercial officer of Nestle's Prometheus Laboratories Inc. unit, formerly chief commercial officer at EKR Therapeutics Inc.  ...
BC Week In Review | Oct 24, 2011
Company News

EKR board of directors update

EKR Therapeutics Inc. , Bedminster, N.J.   Business: Neurology, Cardiovascular   Resigned: Rolf Classon as chairman  ...
BC Week In Review | Oct 11, 2010
Clinical News

Cardene I: Phase IV data

The open-label, U.S. Phase IV CLUE trial in 226 patients admitted to the emergency room with 2 SBP readings of >180 mmHg measured >=10 minutes apart showed that a significantly greater proportion of patients receiving...
Items per page:
1 - 10 of 43
BC Week In Review | Aug 5, 2013
Company News

Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news

Cornerstone filed a suit in the U.S. District Court for the District of Delaware alleging that an sNDA submitted by Exela for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine in 0.9% sodium chloride...
BC Week In Review | Jun 17, 2013
Company News

Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news

Cornerstone received a Paragraph IV notification letter from Exela PharmaSci's Exela Pharma Sciences LLC (Lenoir, N.C.) subsidiary indicating that it submitted an sNDA to FDA for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine...
BioCentury | Apr 22, 2013
Emerging Company Profile

Cardiorentis: Keeping heart

Cardiorentis AG is the fifth company to take on development of ularitide for acute heart failure. Armed with more than €100 million ($129.9 million) from undisclosed investors and expecting to have to do a smaller...
BC Week In Review | Sep 24, 2012
Company News

Dara BioSciences, Helsinn Group sales and marketing update

Helsinn granted Dara exclusive, U.S. rights to commercialize Gelclair povidone. The bioadherent oral gel is approved in the U.S. to treat oral mucositis. Dara plans to launch Gelclair in 1Q13. Dara and Helsinn declined to...
BC Week In Review | Sep 10, 2012
Company News

Civitas management update

Civitas Therapeutics Inc. , Chelsea, Mass.   Business: Drug delivery, Neurology, Pulmonary   Hired: Bryan Stuart as CBO, formerly chief of corporate development of EKR Therapeutics Inc. , which Cornerstone Therapeutics Inc. acquired  ...
BC Week In Review | Jul 2, 2012
Company News

Cornerstone Therapeutics, EKR deal

Cornerstone acquired EKR for $125 million in cash plus up to $25 million in milestones over the next three years (see BioCentury, May 21). Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C.   EKR Therapeutics Inc. , Bedminster,...
BC Week In Review | May 21, 2012
Company News

Cornerstone Therapeutics, EKR deal

Cornerstone will acquire EKR for $125 million in cash plus up to $25 million in milestones over the next three years. Cornerstone said the deal expands its product offerings and commercial infrastructure in the hospital...
BC Week In Review | Feb 13, 2012
Company News

Nestle management update

Nestle S.A. (SIX:NESN), Vevey, Switzerland   Business: Gastrointestinal, Autoimmune, Diagnostic   Hired: Anthony Yost as SVP and chief commercial officer of Nestle's Prometheus Laboratories Inc. unit, formerly chief commercial officer at EKR Therapeutics Inc.  ...
BC Week In Review | Oct 24, 2011
Company News

EKR board of directors update

EKR Therapeutics Inc. , Bedminster, N.J.   Business: Neurology, Cardiovascular   Resigned: Rolf Classon as chairman  ...
BC Week In Review | Oct 11, 2010
Clinical News

Cardene I: Phase IV data

The open-label, U.S. Phase IV CLUE trial in 226 patients admitted to the emergency room with 2 SBP readings of >180 mmHg measured >=10 minutes apart showed that a significantly greater proportion of patients receiving...
Items per page:
1 - 10 of 43